CA3194764A1 - Compositions suitable for use in neonates - Google Patents

Compositions suitable for use in neonates

Info

Publication number
CA3194764A1
CA3194764A1 CA3194764A CA3194764A CA3194764A1 CA 3194764 A1 CA3194764 A1 CA 3194764A1 CA 3194764 A CA3194764 A CA 3194764A CA 3194764 A CA3194764 A CA 3194764A CA 3194764 A1 CA3194764 A1 CA 3194764A1
Authority
CA
Canada
Prior art keywords
weeks
composition
months
igf
polysorbate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194764A
Other languages
English (en)
French (fr)
Inventor
Nazila Salamat-Miller
Katherine Taylor
Bing He
Indranil Bhattacharya
Linda HAN
Benita AMSDEN
James KRANZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oak Hill Bio Ltd
Original Assignee
Oak Hill Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oak Hill Bio Ltd filed Critical Oak Hill Bio Ltd
Publication of CA3194764A1 publication Critical patent/CA3194764A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3194764A 2020-10-19 2021-10-19 Compositions suitable for use in neonates Pending CA3194764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093696P 2020-10-19 2020-10-19
US63/093,696 2020-10-19
PCT/US2021/055598 WO2022086953A1 (en) 2020-10-19 2021-10-19 Compositions suitable for use in neonates

Publications (1)

Publication Number Publication Date
CA3194764A1 true CA3194764A1 (en) 2022-04-28

Family

ID=78622033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194764A Pending CA3194764A1 (en) 2020-10-19 2021-10-19 Compositions suitable for use in neonates

Country Status (24)

Country Link
US (1) US20230381285A1 (enExample)
EP (2) EP4534073A3 (enExample)
JP (1) JP7827315B2 (enExample)
KR (1) KR20230113287A (enExample)
CN (1) CN117098547A (enExample)
AU (1) AU2021364523A1 (enExample)
CA (1) CA3194764A1 (enExample)
DK (1) DK4228676T3 (enExample)
ES (1) ES3005966T3 (enExample)
FI (1) FI4228676T3 (enExample)
HR (1) HRP20250193T1 (enExample)
HU (1) HUE070409T2 (enExample)
IL (1) IL301688A (enExample)
LT (1) LT4228676T (enExample)
MX (1) MX2023004426A (enExample)
PL (1) PL4228676T3 (enExample)
PT (1) PT4228676T (enExample)
RS (1) RS66493B1 (enExample)
SA (1) SA523440271B1 (enExample)
SI (1) SI4228676T1 (enExample)
SM (1) SMT202500093T1 (enExample)
TW (1) TWI912393B (enExample)
WO (1) WO2022086953A1 (enExample)
ZA (1) ZA202303162B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025502349A (ja) 2022-01-19 2025-01-24 オーク ヒル バイオ リミテッド Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法
WO2023242439A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
KR20250079196A (ko) * 2022-10-04 2025-06-04 오크 힐 바이오 리미티드 Igf-1 복합체를 이용한 신생아 치료 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
HK1217633A1 (zh) * 2013-01-15 2017-01-20 Teva Pharmaceutical Industries Ltd. 冻乾方法
KR20140119396A (ko) * 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20200097679A (ko) * 2017-09-11 2020-08-19 샤이어 휴먼 지네틱 테라피즈 인크. 만성 폐 질환 치료를 위한 방법 및 조성물
JP2025502349A (ja) * 2022-01-19 2025-01-24 オーク ヒル バイオ リミテッド Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants

Also Published As

Publication number Publication date
DK4228676T3 (da) 2025-01-20
ES3005966T3 (en) 2025-03-17
SA523440271B1 (ar) 2025-04-10
HUE070409T2 (hu) 2025-06-28
SI4228676T1 (sl) 2025-03-31
ZA202303162B (en) 2024-08-28
WO2022086953A9 (en) 2022-07-07
CN117098547A (zh) 2023-11-21
RS66493B1 (sr) 2025-03-31
JP7827315B2 (ja) 2026-03-10
FI4228676T3 (fi) 2025-02-26
US20230381285A1 (en) 2023-11-30
HRP20250193T1 (hr) 2025-04-11
PT4228676T (pt) 2025-01-24
IL301688A (en) 2023-05-01
KR20230113287A (ko) 2023-07-28
JP2023550203A (ja) 2023-11-30
EP4228676B1 (en) 2025-01-08
EP4534073A3 (en) 2025-05-14
MX2023004426A (es) 2023-08-04
LT4228676T (lt) 2025-02-10
WO2022086953A1 (en) 2022-04-28
TWI912393B (zh) 2026-01-21
AU2021364523A1 (en) 2023-04-06
SMT202500093T1 (it) 2025-03-12
EP4534073A2 (en) 2025-04-09
PL4228676T3 (pl) 2025-04-07
EP4228676A1 (en) 2023-08-23
TW202233228A (zh) 2022-09-01

Similar Documents

Publication Publication Date Title
US20230381285A1 (en) Compositions suitable for use in neonates
EP3824876B1 (en) Long-acting formulations of insulins
AU2024227601B2 (en) Methods and compositions for treating chronic lung diseases
HK40099225B (en) Compositions suitable for use in neonates
HK40099225A (en) Compositions suitable for use in neonates
EA049095B1 (ru) Композиции, подходящие для применения у новорожденных
Sanjaya et al. The effect of maternal diabetes on the formation of fetal surfactant
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
HK40033881A (en) Methods and compositions for treating chronic lung diseases
Nagesh Surfactant replacement therapy in neonates

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250929

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250929

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251010

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251011

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251215

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251215

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251215

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251215

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217